Notícias

RapAdmin

CholineAndCognition-2
CholineAndCognition-22752×1536 430 KB

This systematic review and dose-response meta-analysis pooled nine independent observational cohorts covering 218,378 adults, mostly middle-aged and older, from China, the United States, the United Kingdom and Finland. People with the highest dietary choline intake had about 24 percent lower odds of a combined set of adverse cognitive outcomes than those with the lowest intake. Odds were about 33 percent lower for objectively measured cognitive impairment or decline and about 26 percent lower for Alzheimer’s disease. The association with all-cause dementia was not statistically significant. Risk appeared lowest at intakes of roughly 350 to 400 mg per day, close to current dietary guidelines, with no added benefit beyond that. The evidence is entirely observational.

Choline is an underappreciated nutrient. The body uses it to make acetylcholine, a neurotransmitter central to memory and learning, and phosphatidylcholine, a major building block of cell membranes. It also feeds the methylation pathways that regulate gene expression and keep homocysteine in check. The liver can make some choline, but not enough, so diet has to supply the rest. Eggs, meat, fish, liver and soy are the richest sources, and surveys suggest most Americans fall short of the recommended intake.

Because the brain cells that make acetylcholine degenerate early in Alzheimer’s disease, scientists have long wondered whether getting enough choline might help protect cognition. Individual studies have been mixed. This new analysis, led by researchers at Shandong First Medical University, set out to pool the evidence and identify an optimal intake.

The team searched five databases and included 11 articles, eight following people over time and three snapshot studies. After removing overlapping data from the same cohorts, nine independent groups remained. The largest by far were the UK Biobank, with more than 125,000 participants, and two long-running American studies of nurses and health professionals, with about 77,500.

Across all outcomes combined, people in the top choline intake category had 24 percent lower odds of cognitive problems than those in the bottom category. The link was strongest for objectively measured cognitive impairment and decline, and it also reached significance for Alzheimer’s disease. For dementia overall, the pooled estimate pointed in the same direction but could have been due to chance.

The dose-response analysis is the paper’s main selling point. Risk fell as intake rose, reaching its lowest point at around 350 to 400 mg per day, roughly the amount in two and a half large eggs. Beyond that, the curve flattened. That range lines up with European guidance of 400 mg per day and sits slightly below the US recommendations of 425 mg for women and 550 mg for men.

The findings deserve a cautious reading. The biggest and most rigorous cohorts showed weaker associations. In the UK Biobank and a Finnish cohort followed for 22 years, the link with dementia and Alzheimer’s was small and not statistically significant on its own. The strongest effects came from a handful of smaller studies, including one with just 154 participants. When small studies report bigger effects than large ones, that often signals selective publication or other bias.

People who eat more eggs, fish and meat may also differ in income, education, overall diet and health habits, and only four of the studies adjusted for overall diet quality. People in the early stages of cognitive decline may also eat differently, or recall their diets less accurately, which can make choline look protective when it is really a marker of something else.

The big idea is that adequate choline intake, near current guidelines, is associated with somewhat better cognitive aging, and more than that appears to offer no further benefit. This is consistent with choline’s biology. Proving that eating more choline actually prevents cognitive decline will require randomized trials.

Actionable Insights

This analysis cannot establish cause and effect. Its practical value is in pointing toward a reasonable dietary target. [Confidence: Medium]

  1. Aim to meet, not exceed, recommended choline intake: about 400 to 425 mg per day for women and 400 to 550 mg for men. The lowest observed risk was at 350 to 400 mg.
  2. Food first. One large egg provides about 147 mg, 100 g of beef liver about 420 mg, and fish, poultry, soy and cruciferous vegetables contribute smaller amounts. People who avoid animal foods are at higher risk of low intake.
  3. Expect modest effects. Across all outcomes, higher intake was linked to 24 percent lower odds. If 10 percent of a group would develop a cognitive problem over a decade, that would drop to about 7.8 percent, roughly one case avoided per 45 people, if the link were causal. The largest, best-measured cohorts suggest a smaller effect, about 8.7 percent, or one case per 77 people.
  4. There is no evidence that intakes above about 400 mg add benefit. High-dose supplements raise levels of TMAO, a gut-derived metabolite linked to cardiovascular risk, and the adult upper limit is 3.5 g per day.

Context and Source

  • Paywalled Paper: Association of dietary choline intake with cognitive decline and related outcomes: a systematic review and dose-response meta-analysis of observational studies
  • Institution: Shandong First Medical University and Shandong Academy of Medical Sciences (lead), with Shandong Medical and Pharmaceutical University, Shandong Second Medical University and the Jiangnan University-Shandong First Medical University Interdisciplinary Center for Food, Nutrition and Health
  • Country: China
  • Journal: Food and Function (Royal Society of Chemistry)
  • Impact evaluation: The impact score of this journal is 6.3 (2025 Journal Impact Factor, per the publisher; CiteScore 7.8), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal. It sits in the top quartile of food science journals but publishes a high volume of nutrition and bioactive compound papers.

RapAdmin

MitochondriaParkinsons-2
MitochondriaParkinsons-22752×1536 498 KB

This narrative review from two Chinese hospitals argues that mitochondrial dysfunction is a shared mechanism linking normal aging to Parkinson’s disease. The authors summarize evidence that both conditions involve faulty mitochondrial quality control through the PINK1/PARKIN mitophagy pathway, along with accumulating mitochondrial DNA deletions, reduced Complex I activity and depleted NAD+. They also describe disrupted calcium exchange with the endoplasmic reticulum, iron-driven ferroptosis and inflammation triggered by leaked mitochondrial DNA. They describe a vicious cycle in which misfolded alpha-synuclein damages mitochondria, which in turn promotes more alpha-synuclein aggregation. A short final section lists mitochondria-targeted treatments, including antioxidants, GLP-1 drugs, nicotinamide riboside, urolithin A and spermidine.

Age is the strongest risk factor for Parkinson’s disease. Prevalence roughly triples between the late 60s and the 80s. That raises a natural question: does Parkinson’s represent an accelerated or derailed version of something that happens to every aging brain? A new review in Frontiers in Aging Neuroscience argues that the answer lies largely inside our mitochondria.

Dopamine neurons in the substantia nigra are extraordinary energy consumers. Each one sends out a sprawling axonal network with hundreds of thousands of connections and fires continuously in a rhythmic pattern that draws heavily on calcium. That combination makes them unusually dependent on healthy mitochondria and unusually vulnerable when mitochondria falter.

The review walks through the ways mitochondria decline with age and the matching problems seen in Parkinson’s. Damaged mitochondria are normally tagged for disposal by two proteins, PINK1 and PARKIN, in a recycling process called mitophagy. Mutations in either gene cause inherited early-onset Parkinson’s. Mitochondrial DNA accumulates deletions over a lifetime, and these deletions are especially common in the substantia nigra of people with Parkinson’s. The first step of the energy-producing chain, Complex I, loses activity with age and is markedly impaired in Parkinson’s brains. Toxins that block Complex I, such as MPTP and the pesticide rotenone, can produce parkinsonism in humans and animals.

The authors also describe newer threads. Iron accumulates in the aging substantia nigra and can drive ferroptosis, an iron-dependent form of cell death. Mitochondrial DNA that leaks out of damaged organelles can trigger inflammatory alarms in microglia, the brain’s immune cells. Misfolded alpha-synuclein, the protein that clumps into Lewy bodies, binds to mitochondria and impairs them. Damaged mitochondria in turn promote more misfolding.

This is a coherent and largely mainstream picture, and the mitochondrial hypothesis of Parkinson’s has strong roots in human genetics and toxicology. The weaker part of the review is its treatment section. It presents GLP-1 receptor agonists such as exenatide as promising without mentioning that the large phase 3 Exenatide-PD3 trial, published in early 2025, found no benefit. It lists the mitochondria-targeted antioxidant MitoQ as tested in a clinical trial without noting that the trial was negative. It omits the 2022 FAIRPARK-II trial, in which an iron-chelating drug lowered brain iron but made patients worse. Several other large negative trials of mitochondrial and calcium-targeted strategies also go unmentioned.

That pattern matters. The history of Parkinson’s research is littered with mitochondrial strategies that worked in mice and failed in people, including coenzyme Q10, creatine and calcium channel blockers. The one recent GLP-1 success, a 2024 trial of lixisenatide, produced a modest effect at the cost of frequent nausea.

The big idea is that mitochondrial decline may be the soil in which Parkinson’s grows, which would make mitochondrial maintenance a plausible prevention target. Whether any current intervention can deliver on that promise in humans remains unproven.

Actionable Insights

This is a review of mechanisms, mostly from animal and cell studies. It offers no direct evidence that any intervention prevents or slows Parkinson’s in people.

  1. Avoid known mitochondrial toxins. Complex I inhibitors, including the pesticide rotenone, can cause parkinsonism. Reducing pesticide exposure is the most defensible takeaway.
  2. Be skeptical of antioxidant supplements marketed for brain protection. The one human trial of MitoQ in Parkinson’s showed no benefit. Coenzyme Q10 also failed in a 600-person trial.
  3. GLP-1 drugs are not proven for Parkinson’s. Lixisenatide slowed motor decline by about 3 points on a 132-point scale over a year, roughly the smallest change patients notice. Exenatide showed zero benefit over two years.
  4. Do not self-treat with iron chelators. Deferiprone worsened symptoms by about 9 points on a 260-point scale.
  5. NAD+ precursors such as nicotinamide riboside raise brain NAD+ in small studies, but clinical benefit is unestablished.

Context and Source

  • Open Access Paper: Mitochondrial dysfunction in Parkinson’s disease and aging
  • Institution: Taizhou Hospital of Chinese Traditional and Western Medicine (Department of Neurology), Taizhou, Zhejiang; First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou
  • Country: China
  • Journal: Frontiers in Aging Neuroscience (Frontiers Media)
  • Impact evaluation: The impact score of this journal is 4.5 (Journal Impact Factor; CiteScore 8.6), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

BodyFatCognition-2
BodyFatCognition-22752×1536 440 KB

Researchers in the Study of Muscle, Mobility and Aging measured body fat in 769 healthy adults aged 70 to 94 using BMI, waist size and whole-body MRI, then compared it with four cognitive tests. The participants were mostly white and highly educated. People with more body fat scored lower on a processing speed test that times how quickly someone matches symbols to numbers. Each standard deviation increase in adiposity, roughly 13 centimeters of waist, corresponded to about two fewer correct answers. The link survived adjustment for heart disease and diabetes, weakened after accounting for education and depression, and disappeared once physical activity, smoking and alcohol were added.

Midlife obesity is one of the better-established modifiable risk factors for dementia. After 70, the picture gets murky. Some studies find that heavier older adults do worse on cognitive tests. Others find no link, and a few find that extra weight seems protective. Part of the confusion comes from BMI, a crude measure that cannot tell fat from muscle or belly fat from hip fat, and that becomes less meaningful as people shrink and lose muscle with age.

A team led by researchers at the University of Pittsburgh tried to cut through that confusion with better tools. They drew on the Study of Muscle, Mobility and Aging, a deeply characterized group of adults aged 70 and older recruited in Pittsburgh and Winston-Salem, North Carolina. Each participant had a whole-body MRI scan that separated visceral fat, which wraps the internal organs, from subcutaneous fat, which sits under the skin. Participants also completed four cognitive tests covering general screening, processing speed, executive function and verbal memory.

The clearest result involved processing speed. On the Digit Symbol Coding Test, where people match symbols to numbers as fast as they can for a set time, those with more body fat completed fewer items. This held for BMI, waist circumference and most MRI fat measures. Adjusting for heart disease and diabetes changed the picture only slightly.

The association then shrank as more factors were added. Accounting for education and depressive symptoms trimmed it further. Adding physical activity, smoking and alcohol erased it entirely. In the final model, no measure of fat significantly predicted processing speed.

That pattern can be read two ways. One reading is that the fat link was never really about fat, and that people who move more are both leaner and quicker. The other is that physical activity sits on the causal pathway, so that extra fat leads to less movement, which in turn affects brain health. A single snapshot in time cannot separate these possibilities.

Other results cut against expectations. The researchers predicted that visceral fat, the metabolically nastier depot, would be the stronger culprit. It was not. Subcutaneous fat measures tracked processing speed at least as closely. In the fully adjusted model, more subcutaneous fat was linked to slightly better delayed word recall, a finding the authors themselves treat as exploratory.

Body fat showed no relationship with Montreal Cognitive Assessment scores. The authors suggest this widely used screen may be too blunt to detect subtle differences in healthy, well-educated people, most of whom scored near the top of its range.

The participants were healthier, more active and more educated than typical older Americans, and nearly nine in ten were white. People with dementia, severe obesity or limited mobility were excluded. The findings speak to a fortunate slice of the aging population.

The big idea is that in healthy older adults, body fat relates most to how fast the brain works, not to memory or reasoning. That relationship appears closely tied to lifestyle, especially how much people move. For anyone past 70, the practical lesson points toward staying active rather than chasing a number on the scale.

Actionable Insights

This study is a cross-sectional snapshot, so it shows association, not cause.

  1. Prioritize movement. Once physical activity, smoking and alcohol were accounted for, the link between body fat and processing speed shrank by about two thirds and lost significance. Activity appears to be the more important lever.
  2. Waist size is a reasonable cheap marker. In the less adjusted models, each 13 centimeters (about 5 inches) of extra waist matched about 2 fewer correct answers on the speed test. That is roughly the drop seen across 2 to 3 years of age in this cohort.
  3. Do not fear all fat after 70. Subcutaneous fat was not worse than visceral fat, and it was weakly linked to slightly better memory. Aggressive weight loss in late life risks losing muscle.
  4. Ask for a sensitive test. A processing speed test may pick up subtle changes that a standard cognitive screen misses.

How big is the effect? Small. Body fat explained about 2 percent of the differences in processing speed before lifestyle adjustment, and well under 1 percent after. Safety Data Absent for any weight-loss strategy in this age group.

Context and Source

  • Paywalled Paper: Adiposity and Cognitive Performance in Older Men and Women from the Study of Muscle, Mobility and Aging (SOMMA), published 2026 Oct 6.
  • Institution: University of Pittsburgh (lead and corresponding, Division of Endocrinology and Metabolism), with Chatham University, California Pacific Medical Center Research Institute (San Francisco Coordinating Center), University of California San Francisco, Wake Forest University and the AdventHealth Translational Research Institute
  • Country: United States
  • Journal: The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
  • Impact evaluation: Journal Impact Factor; 2025 CiteScore 8.2, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal. It ranks 4th of 49 gerontology journals.

RapAdmin

LowInflammationFasterAging-2
LowInflammationFasterAging-22752×1536 462 KB

Researchers followed 953 women in Cebu, Philippines, and measured chronic inflammation in 2005 with two tools: blood C-reactive protein (CRP) and an epigenetic stand-in calculated from DNA methylation (DNAm-CRP). Seven years later, women with higher baseline inflammation were more likely to develop new physical limitations, trouble with daily activities, diabetes and hypertension. They were also more likely to score low on a cognitive screen. These results held after accounting for starting health, age, smoking, recent infection symptoms, socioeconomic status and blood cell makeup. Each one standard deviation increase in inflammation raised the odds of these outcomes by roughly 40 to 70 percent. Surprisingly, inflammation barely rose with age in this relatively lean population, which challenges the idea that inflammaging is universal. The DNA methylation measure performed as well as the blood test.

Inflammaging is one of the most repeated ideas in longevity science. The story goes that as we age, a slow-burning immune activation creeps upward, damages tissues and drives the diseases of old age. Nearly all the evidence for that story comes from wealthy countries, where obesity is common and baseline inflammation runs high. A new study from the Philippines asks whether the story holds in a very different setting, and the answer is yes and no.

The research team, led by anthropologist Thomas McDade at Northwestern University, drew on the Cebu Longitudinal Health and Nutrition Survey. This cohort has tracked thousands of Filipino women since they were pregnant in 1983. In 2005, when the women were 35 to 69 years old, nurses collected fasting blood samples in their homes. Seven years later, the team measured the same women again across physical function, chronic disease and cognition.

Inflammation was measured two ways. The first was standard high-sensitivity CRP, a liver protein that rises with inflammation. CRP has a known weakness: a cold or a stomach bug can spike it for days, which is a real problem where infections are common. The second was DNAm-CRP, a score built from methylation patterns at 1,468 sites across white blood cell DNA. Methylation changes more slowly, so in principle it records longer-term inflammatory exposure rather than last week’s sniffle.

The first surprise was that inflammation barely tracked age. Plasma CRP rose only slightly with age, and DNAm-CRP actually dipped a little. In this population, the steady age-linked climb at the center of the inflammaging concept was largely missing. These women also had much lower CRP than Americans of the same age.

Yet inflammation still predicted who aged worse. Women with higher DNAm-CRP in 2005 had 1.7 times the odds of having diabetes in 2012 for every standard deviation increase, even after the researchers accounted for whether they already had diabetes in 2005. Higher inflammation also predicted new physical limitations, trouble with daily tasks such as bathing or dressing, and hypertension. Plasma CRP added a link to lower scores on the Mini-Mental State Examination.

To put the total effect in perspective, the team counted how many of 11 health problems each woman had by 2012. Women at the low extreme of DNAm-CRP averaged 2.4 problems. Women at the high extreme averaged 3.7. That spread was about the same as the spread produced by fasting blood glucose, a standard marker of metabolic risk.

The DNA-based score held up well. It was unaffected by adjusting for white blood cell makeup or recent infection symptoms, and it worked equally well in leaner and heavier women. Plasma CRP, by contrast, lost its predictive power among women with larger waists.

The catch is that the effects were modest, and they showed up only after age 50. Among women under 50, neither measure predicted much. The study is also observational, so it cannot show that lowering inflammation would change anyone’s trajectory.

The big idea is that chronic inflammation can predict aging outcomes even in a population where it does not rise with age. That suggests the danger lies in your individual inflammatory set point rather than in an inevitable age-related climb. If that holds up, inflammation is something to measure and manage, not something to accept as part of getting older.

Actionable Insights

This study did not test any treatment, so every practical message here is inferred, not proven.

First, know your number. High-sensitivity CRP is an inexpensive, widely available blood test. In this study, a baseline CRP above 3 mg/L predicted higher risk of physical limitations, diabetes and hypertension over seven years. Test when you are healthy, because a reading above 10 mg/L usually reflects an acute infection and should be repeated.

Second, being lean is not full protection. These women were relatively slim by Western standards, yet inflammation still predicted their health trajectories.

Third, the payoff window appears to open after 50, when the associations became clear and grew stronger past 60.

How big is the effect? Moving one standard deviation up the inflammation scale was linked to roughly 40 to 70 percent higher odds of the outcomes measured. For diabetes, that roughly means going from a 14 percent risk to about 22 percent. Comparing the least and most inflamed women, the gap was about one extra health problem (2.4 versus 3.7) over seven years. In statistical terms, these are small effects, about the size of the risk carried by fasting blood sugar. Any lifestyle or drug approach to lowering CRP draws on other research: Safety Data Absent from this paper.

Context and Source

  • Paywalled Paper: Chronic inflammation and multiple dimensions of aging among women in the Philippines
  • Institution: Northwestern University (lead, Department of Anthropology and Institute for Policy Research), with University of North Carolina at Chapel Hill, Columbia University, University of San Carlos Office of Population Studies Foundation (Cebu), University of British Columbia and Harvard University
  • Country: United States (lead institution); cohort based in the Philippines; epigenetic work in Canada
  • Journal: The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
  • Impact evaluation: This is a Medium impact journal. Within its own field it ranks 4th of 49 gerontology journals, so it is a respected specialist venue.

RapAdmin

MeasuringIntrinsicCapacity-2
MeasuringIntrinsicCapacity-22752×1536 448 KB

Researchers at Hebrew SeniorLife’s Marcus Institute for Aging Research and Beth Israel Deaconess Medical Center used 2022 data from 5,834 community-dwelling adults aged 65 and older in the National Health and Aging Trends Study (NHATS), representing about 50 million Medicare beneficiaries. They built and validated a measure of intrinsic capacity (IC), the World Health Organization’s concept of a person’s combined physical and mental abilities. Statistical modeling supported a structure with one overall IC factor plus six domains: cognition, locomotion, vision, hearing, vitality and psychological health. Walking speed and balance were the strongest contributors to the overall score. The model fit very well. A simpler WHO screening tool, ICOPE, correlated strongly with the full score (r = 0.71). People in the lowest quarter of IC were far more likely to be frail (77% vs 1.4% in the highest quarter) or disabled.

Medicine has traditionally tracked aging through diseases: diabetes, heart disease, dementia. The World Health Organization has pushed a different approach. Its concept of intrinsic capacity asks how much physical and mental reserve a person has, regardless of diagnoses. The idea is that declining function can be spotted and treated before it becomes disability. WHO’s ICOPE program offers a short screening tool for primary care. Both have been tested in Europe, China and Latin America, but until now not in a nationally representative US sample.

This study fills that gap using NHATS, a long-running federal survey that visits Medicare beneficiaries at home. In 2022, interviewers measured balance, walking speed, chair rises, grip strength, lung function, hearing and vision, and gave memory and thinking tests and mental health questionnaires. The researchers asked which of these measures cluster together and whether they reflect one underlying capacity.

The answer was a clear yes, with nuance. The data fit a “bifactor” model best: every measure reflected a single general IC factor plus one of six specific domains. Walking speed (loading 0.73) and balance (0.66) were the strongest markers of overall capacity, followed by memory and orientation tests. Hearing and vision formed their own separate domains, supporting WHO’s six-domain screening approach over the older five-domain version. Lung function, measured as peak expiratory flow, turned out to be a better marker of vitality than body weight or waist size, both of which dropped out. Sleep also dropped out. Loneliness stayed in as part of psychological health.

The score behaved as expected. It was lower in older people, women, those with less income and education, and those living alone or socially isolated. Among people in the lowest quarter of IC, 77% were frail and 40% needed help with basic daily activities such as bathing or dressing. In the highest quarter, those figures were 1.4% and 2.2%. The WHO’s quick screening tool, which scores six domains from 0 to 12, tracked closely with the full measure.

The team also produced reference curves showing how IC typically declines with age for men and women. The spread widens dramatically at older ages: some people in their 90s score like average 70-year-olds, while others fall far below. That variation is exactly what the IC concept is meant to capture.

There are limits. The study is a single snapshot, so it cannot yet show that a low score predicts future disability, hospitalization or death. Some validation is partly circular, because the dementia classification used in NHATS draws on the same memory and orientation tests built into the IC score. The study excluded people in nursing homes, the group with the lowest capacity.

For clinicians and older adults, the practical message is that a handful of quick tests capture a meaningful picture of overall health. Walking speed, balance, chair rises, grip, lung function, hearing, vision, memory and mood are all measurable and many are modifiable.

Actionable Insights

  1. Walking speed and balance carry the most information about overall capacity. Gait loaded 0.73 on general IC. Track your usual walking speed and single-leg or tandem balance over time.
  2. Don’t overlook hearing and vision. They formed distinct domains with strong loadings (hearing 0.86 to 0.87). Hearing aids and cataract surgery are among the most effective fixes available.
  3. Peak expiratory flow, a cheap handheld test, is a useful vitality marker. Respiratory muscle training and aerobic exercise can improve it.
  4. The contrast between quarters is very large. Frailty was 77% in the lowest IC quarter vs 1.4% in the highest, roughly a 55-fold difference. ADL disability was 39.5% vs 2.2% (about 18-fold). These are cross-sectional associations.
  5. Loneliness belongs in health checkups. It loaded on psychological capacity (0.42).
  6. The WHO ICOPE screen (scored 0 to 12) is a practical proxy. A score of 9 or less identified the group with a 58.5% frailty prevalence.

Context and Source

  • Paywalled Paper: Intrinsic Capacity in a Nationally Representative US Population
  • Institutions: Marcus Institute for Aging Research, Hebrew SeniorLife, Boston; Beth Israel Deaconess Medical Center; Kyung Hee University Medical Center, Seoul
  • Countries: United States, with South Korea
  • Journal: The Journals of Gerontology, Series A: Medical Sciences
  • Impact evaluation: The impact score of this journal is approximately 4.6, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

WalkingSpeedAfter90-2
WalkingSpeedAfter90-22752×1536 382 KB

Researchers at UC Davis, UC Irvine and Kaiser Permanente studied 502 adults aged 90 and older in LifeAfter90, a racially and ethnically diverse cohort of Kaiser Permanente Northern California members. Participants averaged 92.9 years and walked at a usual pace of 0.55 m/s on a 4-meter walk test. Over an average of 3.6 years, 259 died. After adjustment for age, sex, race and ethnicity, and education, each 0.21 m/s faster gait speed (about 2 seconds faster over 4 meters) was associated with 20% lower risk of death. The fastest third of walkers had 33% lower risk than the slowest third, and walking below 0.8 m/s carried about 74% higher risk. The association held for those aged 90 to 94 but disappeared at 95 and older. It also appeared in women but not clearly in men, and in people walking without a device but not in device users, though formal tests found no differences by sex, race and ethnicity, or device use.

Gait speed is sometimes called the sixth vital sign. Large studies of older adults show that how fast someone walks at a comfortable pace predicts disability, dementia and death about as well as complicated risk models. Most of that evidence, though, comes from people in their 60s, 70s and 80s, mostly white. Adults over 90, the fastest-growing age group in many countries, are rarely studied.

This brief report from the LifeAfter90 study, based in the San Francisco Bay Area and Sacramento, helps fill that gap. Researchers visit participants at home every six months. Some 64% of the analyzed participants were non-white, including large Asian, Black and Latinx groups, a rare level of diversity for the oldest-old.

Participants walked 4 meters at their usual pace twice, using a cane or walker if they needed to. Their average speed was 0.55 meters per second, about 7 seconds for the 4 meters. Men walked slightly faster than women. Two in five used a walking aid.

Over roughly 3.6 years, just over half the participants died, an annual mortality rate of about 14%. Faster walkers clearly fared better. Each step up of about two seconds on the 4-meter walk went with 20% lower risk of death. Those in the fastest third lived noticeably longer, with survival curves separating within the first two years. People walking slower than 0.8 m/s, a common clinical threshold, had about 74% higher risk than faster walkers.

The pattern was not uniform. Among people aged 90 to 94, faster walking was linked to 30% lower risk per two-second improvement. Among those aged 95 and older, the association vanished. At that extreme age, the authors suggest, death may depend more on acute events than on physical reserve, or the survivors may already be a uniquely hardy group. The association was evident in women and in people walking without a device, but not clearly in men or device users. Statistical tests did not confirm these as true differences.

The study’s most important weakness is who was measured. Of 1,364 participants, 790 had no gait speed recorded, mostly because the test was skipped to reduce visit length and fatigue. Another 72 were excluded because they couldn’t or didn’t attempt the walk, or needed physical help. The analysis therefore represents a somewhat healthier subset. The researchers also adjusted only for demographic factors, not for disease, so gait speed may partly stand in for heart failure, lung disease or cognitive decline.

The practical message is straightforward. A quick, cheap walk test remains informative into the tenth decade of life, at least until about 95, and could help clinicians identify the oldest patients who need closer attention.

Actionable Insights

  1. Time your 4-meter walk at a comfortable pace. Below 0.8 m/s (more than 5 seconds for 4 meters) was associated with about 1.7 times the mortality risk in this 90+ group (HR 1.74).
  2. Small differences matter. About 2 seconds faster on the 4-meter walk (0.21 m/s) corresponded to 20% lower death risk. That is consistent with large studies showing about 12% lower risk per 0.1 m/s in younger older adults.
  3. In absolute terms, by my reading of the survival curves, about 30% of the slowest third died within 2 years versus roughly 10% of the fastest third. That is a large absolute gap in a high-risk group. [Confidence: Low to Medium]
  4. Gait speed reflects reserve. Whether improving it extends life is unproven. Resistance and balance training reliably improve strength in very old adults, as Fiatarone’s nonagenarian study showed, but typically raise gait speed only modestly (about 0.05 to 0.1 m/s).
  5. After 95, walking speed was not predictive here, so don’t over-interpret it at that age.

Context and Source

  • Paywalled Paper: Gait Speed and Survival in Those With Exceptional Longevity: The LifeAfter90 Study
  • Institutions: University of California, Davis; University of California, Irvine; Kaiser Permanente Northern California (Pleasanton)
  • Country: United States
  • Journal: Journal of the American Geriatrics Society
  • Impact evaluation: The impact score of this journal is approximately 6.3, evaluated against a typical high-end range of 0 to 60+ for top general science and medicine, therefore this is a Medium impact journal. It is the leading specialty journal in clinical geriatrics.

RapAdmin

HormonesAndBodyClocks-2
HormonesAndBodyClocks-22752×1536 509 KB

This narrative review by circadian and neuroendocrine researchers in Germany, the UK, Spain and France describes the two-way relationship between the body’s master clock, the suprachiasmatic nucleus (SCN), and steroid hormones: cortisol-type glucocorticoids, estradiol, progesterone and testosterone. The SCN and tissue clocks set the daily timing of hormone release, and those hormones feed back to adjust clock gene expression, rhythm strength and the synchrony of cellular clocks. The authors trace this interplay across life. Before birth, the mother’s glucocorticoid rhythm helps set the fetal clock. In reproductive years, ovarian hormones remodel clocks throughout the reproductive axis, and the clock times the ovulation-triggering LH surge. With aging, hormone rhythms flatten and clock coordination weakens. The review closes with chronotherapy examples, such as morning steroid dosing for asthma.

Hormones and circadian rhythms are usually studied separately, but this review argues they function as a single system. The master clock in the hypothalamus, a cluster of about 20,000 neurons called the suprachiasmatic nucleus, sets the timing of hormone release across the day. Those same hormones then feed back to the clock, tuning its strength and coordination.

The relationship works through several layers. Glucocorticoids, the family that includes cortisol, bind receptors that switch on core clock genes such as Per1 in tissues throughout the body. This is one way the brain’s clock synchronizes the liver, muscle and other organs. The master clock itself resists being reset by glucocorticoids in adulthood, but it still responds to them, partly through its supporting astrocytes. Sex hormones act differently in males and females. Estrogen receptors cluster in the outer shell of the SCN in females, while androgen receptors concentrate in the core in males. That may help explain sex differences in how the clock responds to light.

The review traces this partnership through three life stages.

Before birth, the fetus can’t see light, so the mother’s daily cortisol rhythm acts as one of its main timing signals. Rodent studies suggest that glucocorticoid exposure at the “wrong” time of day has lasting effects on the offspring’s immune, behavioral and metabolic health. That matters clinically, because synthetic steroids are given to most pregnant women at risk of premature delivery without attention to timing.

During reproductive life, clocks run at every level of the reproductive system: the brain, pituitary, ovaries and uterus. Ovulation depends on a well-timed surge of luteinizing hormone. In rodents, this surge occurs only when rising estrogen coincides with a daily signal from the SCN. Removing the SCN abolishes it. In mice, a light schedule mimicking shift work for four weeks eliminated the surge, with effects persisting after normal light returned. Human epidemiology links shift work to menstrual irregularity and adverse pregnancy outcomes.

With aging, both systems lose robustness. Cortisol rhythms flatten, mostly because nighttime cortisol rises. Melatonin rhythms decline. In aging female mice, the four- to five-day activity pattern tied to the estrous cycle fades as ovarian function declines. In older rodents, electrical activity in the SCN is markedly dampened, even though molecular clock gene rhythms seem relatively preserved. Perimenopause in women brings hormone instability that likely contributes to sleep disruption. In a counterintuitive result, restoring testosterone in old castrated male mice reduced activity, whereas in young mice it increased activity.

The final section discusses chronotherapy. The clearest examples involve glucocorticoids. Morning dosing of steroids for asthma improved lung function with less suppression of the stress-hormone system than spread-out dosing. In Cushing’s syndrome, evening dosing of osilodrostat improved cortisol rhythms and sleep. Evidence for timing sex hormones or breast cancer endocrine therapy is preliminary or mixed.

The review is clearly written and well referenced, but it is a narrative synthesis, much of it drawn from rodent work. It does not grade evidence or provide numbers on how much rhythm changes affect health. Its value is conceptual: it reframes hormone health partly as a question of timing.

Actionable Insights

  1. Keep a regular daily schedule. Consistent light exposure, sleep and meal timing support clock-hormone coordination. In mice, four weeks of shift-work-like light schedules abolished the ovulation-triggering hormone surge.
  2. If you take oral glucocorticoids such as prednisone, morning dosing usually mirrors the natural cortisol rhythm. Older asthma studies found morning dosing improved bronchial function with less HPA suppression than dosing spread across the day. Discuss timing with your doctor.
  3. Measure testosterone in the morning. Levels peak early in the day, especially in younger men.
  4. During perimenopause, sleep disruption may partly reflect hormone-clock instability. Lower estradiol and higher FSH were associated with more nighttime awakenings. Hormone therapy remains the most effective treatment for hot flashes.
  5. A flattened cortisol rhythm (high at night) is a marker of circadian aging. Salivary cortisol at waking and bedtime is an inexpensive way to check it.
  6. No effect sizes are provided for any of these benefits. Most evidence is from animals.

Context and Source

  • Open Access Paper: Clocks and steroids interaction across the life span
  • Institutions:
    • University of Lübeck (Germany)
    • University of Bristol (UK)
    • Achucarro Basque Center for Neuroscience and Ikerbasque (Spain)
    • CNRS Institute of Cellular and Integrative Neurosciences, University of Strasbourg (France)
  • Countries: Germany, United Kingdom, Spain, France
  • Journal: Journal of Neuroendocrinology (Wiley), 1 October 2026.
  • Impact evaluation: The impact score of this journal is approximately 5.35, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

TeaDrinkingCardioRisks-2
TeaDrinkingCardioRisks-22752×1536 484 KB

Researchers from the Chinese Academy of Medical Sciences, Peking University and collaborators analyzed 485,934 adults from the China Kadoorie Biobank, followed for an average of 9 years. About 31% drank tea at least three days a week. These habitual tea drinkers had an 11% lower hazard of vascular disease overall than non-habitual drinkers, with lower hazards for coronary heart disease, heart attack and ischemic stroke. The associations depended on how tea was consumed. Moderate-strength tea and room-temperature or hot tea were linked to lower risk, while “burning hot” tea was linked to 16% higher risk. Among weekly drinkers, the lowest risk occurred at roughly 6 to 8 cups a day, with no added benefit above about 15. Habitual tea drinking, not smoking and high physical activity together were associated with 45% lower risk. Tea’s association was weaker among people who were already very active.

Tea is the world’s most widely consumed beverage after water, and its polyphenols have long been suspected of protecting blood vessels. The China Kadoorie Biobank, one of the largest health studies ever run, offers an unusual chance to test that link in a population where tea drinking is deeply embedded in daily life.

This analysis followed nearly half a million adults from ten regions of China, recruited between 2004 and 2008. Participants described their tea habits in detail: how often they drank, how many cups, which type, how strong and how hot. During about nine years of follow-up, nearly 15,000 developed some form of vascular disease, including heart attacks, strokes, lung-related heart disease and peripheral artery problems.

After adjustment for age, sex, education, income proxies, smoking, alcohol, physical activity, body weight and a long list of existing conditions, habitual tea drinkers had 11% lower risk of vascular disease overall. The pattern held for heart disease, heart attack and ischemic stroke, the most common type of stroke. It did not hold for hemorrhagic stroke or pulmonary heart disease.

How people drank tea mattered. Moderate-strength tea was linked to the lowest risk. Room-temperature and hot tea were linked to about 17 to 18% lower risk, while tea described as “burning hot” was linked to 16% higher risk. That fits earlier evidence connecting very hot drinks to esophageal injury and cancer. Black tea showed stronger associations than green tea, unexpected because most earlier studies favor green tea.

Among regular drinkers, risk fell steadily to a low point of about 6 to 8 cups a day and then crept back up, losing its apparent advantage above roughly 15 cups. The authors caution against reading this as a recommendation, since cup size was never standardized.

When tea was combined with other habits, the lowest risk appeared in people who drank tea, did not smoke and were physically active, about 45% lower than in inactive, non-tea-drinking smokers. Tea’s association looked strongest in people with obesity, and it faded among the most active participants. That suggests tea and exercise may affect overlapping pathways.

There are reasons for skepticism. Tea drinkers in this cohort were very different from non-drinkers: nearly two-thirds were men, about half were current smokers (vs one in five non-drinkers), and more drank alcohol. Statistical adjustment can reduce but not erase such differences. Some results are hard to believe: black tea drinkers had roughly 60% lower risk of coronary heart disease, and tea drinkers overall had about 52% lower risk of “other cerebrovascular disease.” Effects of that size from a beverage point to regional differences, chance or unmeasured confounding rather than biology. The study also could not account for coffee drinking or diet.

Even so, the core finding fits a large body of evidence. Moderate tea drinking, especially when not scalding hot, appears compatible with better vascular health. It is best viewed as one part of a healthy lifestyle, with smoking avoidance and exercise carrying far stronger causal evidence.

Actionable Insights

  1. Habitual tea drinking was associated with about 11% lower vascular disease risk (HR 0.888).
  • In absolute terms, about 3.1% of participants developed vascular disease over 9 years (about 3.4 per 1,000 per year).
  • An 11% relative reduction corresponds to roughly 0.35 percentage points over 9 years: about 1 fewer case per 290 tea drinkers (computed, assuming causality).
  1. Avoid scalding hot tea. “Burning hot” tea carried 16% higher vascular risk and is classified by IARC as a probable esophageal carcinogen (above 65°C). Let tea cool for a few minutes.
  2. Moderate strength and moderate amounts looked best. The lowest risk appeared around 6 to 8 cups a day, with no apparent benefit beyond about 15 cups. Cup size was not standardized, so treat this as approximate.
  3. Tea does not offset smoking. Tea-drinking smokers still had higher risk than tea-drinking non-smokers.
  4. If you’re already very active, tea may add little. Its association was not significant in the high-activity group.
  5. For green tea extract supplements: the cardiovascular associations here come from brewed tea, not extracts. High-dose EGCG supplements (roughly 800 mg/day or more) have been linked to liver injury.

Context and Source

  • Paywalled Paper: Habitual tea consumption is associated with lower cardiovascular disease risk
  • Institutions:
    • School of Health Policy and Management and School of Population Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College
    • Peking University Health Science Center
    • University of Hong Kong; Sun Yat-sen University
    • China Kadoorie Biobank Collaborative Group (with Oxford)
  • Country: China
  • Journal: Journal of Internal Medicine (Wiley)
  • Impact evaluation: The impact score of this journal is approximately 9, evaluated against a typical high-end range of 0 to 60+ for top general science and medicine, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

KetoscidosisSGLT2risksLong-2
KetoscidosisSGLT2risksLong-22752×1536 468 KB

Researchers at Karolinska Institutet, Statens Serum Institut and Scandinavian partners used nationwide registers from Sweden, Denmark and Norway to study ketoacidosis in 282,282 adults with type 2 diabetes on SGLT2 inhibitors (mainly empagliflozin and dapagliflozin), covering 322,597 treatment episodes from 2013 to 2022. Over a median of 1.3 years, 1,452 ketoacidosis events occurred, 2.43 per 1,000 person-years. Risk was highest in the first six months but persisted for years. In a nested case-control analysis, the strongest risk factors were: Very high HbA1c (83 mmol/mol or higher, about 9.7%): odds ratio 15, Malnutrition, previous ketoacidosis and BMI under 20: odds ratios about 10, Recent hypoglycemia: odds ratio about 5. Infection was the most common precipitating event, present in about a third of cases. Alcohol intoxication, acute kidney events, acute abdominal conditions, stroke and major surgery showed the strongest associations.

SGLT2 inhibitors such as canagliflozin, empagliflozin and dapagliflozin have become cornerstone treatments for type 2 diabetes, heart failure and chronic kidney disease. They lower blood sugar by making the kidneys excrete glucose, and they reduce heart and kidney events. In longevity circles, interest grew after canagliflozin extended lifespan in male mice in the NIH Interventions Testing Program. Their main serious side effect is ketoacidosis, a dangerous buildup of acids in the blood. Because blood sugar may be only modestly elevated, it can be missed.

Clinical trials show the risk roughly doubles or triples with these drugs. Trials enrolled carefully selected patients and often excluded people with poor glucose control or prior ketoacidosis. This Scandinavian study looked at what happens in everyday practice, using the region’s comprehensive health registers.

Among more than 280,000 people with type 2 diabetes, ketoacidosis occurred at a rate of about 2.4 per 1,000 people per year, higher than in most trials. The risk peaked in the first six months but did not disappear afterward. Later periods still carried roughly two-thirds of the early risk. People who had been on diabetes medication for seven years or more were at higher risk, consistent with gradual loss of insulin production over time.

To identify who is most vulnerable, the researchers compared each person who developed ketoacidosis with up to ten similar users who did not. The clearest warning signs pointed to insulin deficiency:

  • Very poor glucose control
  • Malnutrition
  • Low body weight
  • Previous ketoacidosis
  • Recent episodes of low blood sugar

Some of these patients may actually have had a slow-onset form of type 1 diabetes misclassified as type 2. Alcohol misuse, psychiatric illness, antipsychotic medications and pancreatic disease also raised risk. Living with a partner and higher BMI were associated with lower risk.

Acute events often set things off. Infection was present in nearly a third of cases. The strongest associations were with alcohol intoxication, acute kidney problems, acute abdominal conditions, stroke and major surgery, each linked to odds ratios of roughly 15 to 50. The authors caution that some of these figures are inflated, because healthy controls rarely visited a doctor and so would have had milder events recorded less often.

The consequences were serious. More than one in ten people died within weeks of ketoacidosis, though many deaths were probably driven by the underlying illness. A year later, insulin use had more than doubled, from 32% to 73%. Still, one in four continued their SGLT2 inhibitor.

A comparison with other diabetes drugs was revealing. Among users of DPP-4 inhibitors, which don’t raise ketoacidosis risk, the same risk factors carried similar weight. SGLT2 inhibitors seem to amplify a general vulnerability rather than create new risk factors. Compared with GLP-1 drugs, they roughly doubled overall ketoacidosis risk.

The study relies on diagnosis codes rather than blood test results, so some cases may be misclassified, and it cannot prove that each precipitating event came first. But its size, completeness and multi-country design make it the most detailed real-world picture yet. The authors’ advice is practical: assess risk throughout treatment, and tell patients to pause the drug during acute illness, before surgery and during periods of stress.

Actionable Insights

  1. Absolute risk is low for most people with diabetes. 2.43 events per 1,000 person-years is about 0.24% per year. The authors estimate the drug-attributable excess at roughly 0.12 to 0.16% per year, about 1 extra case per 625 to 833 people treated for a year.
  2. Risk varies enormously. Using the reported case-control distributions, I estimated approximate rates (computed, rough):
  • HbA1c 83 or higher: about 10 per 1,000 per year (1%)
  • HbA1c 52 or lower: about 0.8 per 1,000 per year
  • Previous ketoacidosis or malnutrition: about 20 or more per 1,000 per year
  1. Pause the drug during acute illness, vomiting or reduced food intake, and before planned surgery. US labeling advises stopping canagliflozin, dapagliflozin and empagliflozin at least 3 days before, and ertugliflozin at least 4 days before scheduled surgery.
  2. Avoid binge drinking on SGLT2 inhibitors; alcohol intoxication carried the highest odds ratio (50, likely overstated).
  3. For healthy, insulin-sufficient people, ketoacidosis on an SGLT2 inhibitor is very rare. In the large trials that enrolled people without diabetes, there was one case among about 7,356 people on the drug (EMPA-KIDNEY), and none in the heart failure trials (DAPA-HF, DELIVER, EMPEROR-Reduced and EMPEROR-Preserved). In other words, zero cases in over 10,000 non-diabetic patients over a two year period, the approximate length of each of these studies.
  4. For off-label longevity users: this study covered only type 2 diabetes. Avoid combining SGLT2 inhibitors with strict ketogenic diets, prolonged fasting or heavy exercise without adequate carbohydrate. Know the symptoms: nausea, vomiting, abdominal pain, unusual fatigue and rapid breathing, even with normal glucose. Home blood ketone testing is inexpensive.

Context and Source

  • Paywalled Paper: Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study, published 1 September 2026.
  • Institutions:
    • Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm
    • Statens Serum Institut, Copenhagen
    • Swedish National Diabetes Register and University of Gothenburg
    • HUNT Research Center, NTNU, Norway
    • Stanford University; Danish Cancer Institute
  • Countries: Sweden, Denmark and Norway (with US co-authorship)
  • Journal: The Lancet Diabetes & Endocrinology
  • Impact evaluation: The impact score of this journal is approximately 40, evaluated against a typical high-end range of 0 to 60+ for top general science and medicine, therefore this is an Elite impact journal.

Leitura Relacionada:

RapAdmin

SocialConnectionIntrinsicCapacity-2
SocialConnectionIntrinsicCapacity-22752×1536 497 KB

Researchers led from the Chinese University of Hong Kong pooled data from five large aging cohorts: CHARLS (China), ELSA (England), HRS (USA), SHARE (Europe and Israel) and JSTAR (Japan). In 39,021 adults aged 50 and older, they scored social connection from 0 to 5 using marital status, living with others, family contact, contact with friends or relatives, and social activity participation. They related it to intrinsic capacity, the WHO’s composite of locomotion, cognition, psychological health, sensory function and vitality, followed for 2 to 12 years. Higher social connection went with slightly higher intrinsic capacity at baseline, about 0.04 standard deviations per point. The association was strongest for psychological and cognitive domains. Social activity participation and being married or partnered were the most consistent components.

Loneliness and social isolation are increasingly treated as health risks on par with smoking and inactivity. Most evidence linking them to physical and mental decline comes from single countries using different definitions. This study tried to answer the question more rigorously by harmonizing five of the world’s major aging surveys, which share a common design that allows cross-country comparison.

The researchers built a simple social connection score from five yes-or-no indicators: being married or partnered, living with others, weekly contact with family, weekly contact with friends or relatives, and taking part in social activities such as clubs, volunteering or community groups. They measured intrinsic capacity across five domains:

  • Locomotion (how well someone moves)
  • Cognition
  • Psychological health (largely depressive symptoms)
  • Sensory function (vision and hearing)
  • Vitality (a proxy for physiological reserve)

Across nearly 40,000 people, those with more social connection had higher intrinsic capacity when first assessed. The pattern held in four of the five cohorts; the US Health and Retirement Study was the exception, with an effect near zero. The links were clearest for mood and thinking, weaker for mobility, and absent for vision, hearing and vitality.

Of the five ingredients of social connection, participation in social activities stood out. It was associated with roughly three times the difference in intrinsic capacity of the composite score per point. Being married or partnered came next, with a notably strong link in Japan. Contact frequency and living arrangements were less consistent, although living with others mattered more in England.

The most important finding may be the null one. People who were more socially connected at the start did not decline more slowly over the following years. The researchers interpret this cautiously. Social connection may mark people who already have more reserve, thanks to lifelong advantages in education, health and resources. Or it may run partly in reverse: people with better mobility, hearing and mood find it easier to socialize. The study cannot distinguish between these possibilities.

The size of the associations was also small. Moving from the lowest to the highest social connection category corresponded to a difference of about an eighth of a standard deviation in intrinsic capacity. On the study’s 10-point scale, that is roughly a fifth of a point.

The authors draw measured conclusions. They suggest that social connection is a useful marker for identifying older adults with lower functional reserve, and that community programs promoting social participation are a reasonable strategy. They caution against presenting social connection as proven to slow decline. They also note that the health meaning of social ties appears to vary with culture, such as voluntary participation in the US versus obligatory participation in Japan.

Actionable Insights

  1. Social participation is the component most worth cultivating. It showed the strongest association: 0.13 SD higher intrinsic capacity, about 3 times the composite score’s per-point effect. On the 0 to 10 scale, that is roughly 0.2 points (computed): small, but consistent across cohorts.
  2. Benefits look largest for mood and cognition. Per point of social connection, psychological capacity was 0.05 SD higher and cognition 0.03 SD higher. These are very small effects individually (d of 0.03 to 0.05).
  3. High vs low social connection: 0.12 SD difference in intrinsic capacity, a small effect.
  4. For clinicians: asking about social participation and partner status is a cheap screen for lower reserve.
  5. Social isolation has broader evidence linking it to higher mortality in other large studies.

Context and Source

  • Open Access Paper: Social connection and intrinsic capacity in later life across the USA, England, Europe, China, and Japan: a harmonised multicohort longitudinal study
  • Institutions:
    • Jockey Club Institute of Ageing and Department of Medicine and Therapeutics, Chinese University of Hong Kong
    • National Health Research Institutes, Taiwan
    • University of Tokyo
    • Institute of Health Equity, University College London
  • Countries: Hong Kong SAR (China), Taiwan, Japan and United Kingdom; data from the USA, England, Europe and Israel, China and Japan
  • Journal: The Lancet Healthy Longevity, published online 12 October 2026
  • Impact evaluation: SciJournal lists a 2025 impact factor of about 8.9. Clarivate’s official figures for this journal have been reported higher in recent years, roughly in the low teens (from memory, not verified). The impact score of this journal is approximately 9 to 13, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.